Early invasive strategy no benefit 10 years after NSTE-ACS
Robert A. Henderson, D.M., from Nottingham University Hospitals in the United Kingdom, and colleagues reported 10-year outcomes from the Third Randomized Intervention Treatment of Angina (RITA-3) trial. They randomized 1,810 patients with NSTE-ACS to receive routine invasive or selective invasive strategies. Patients were followed annually up to five years, and mortality was documented over 10 years.
The researchers observed no differences in mortality between the routine invasive and selective invasive groups over 10 years (all cause death: 25.1 versus 25.4 percent; P = 0.94; cardiovascular death: 15.1 versus 16.1 percent; P = 0.65). Independent predictors of 10-year mortality included age, previous myocardial infarction, heart failure, smoking status, diabetes, heart rate, and ST-segment depression, in multivariate analysis.
"The advantage of reduced mortality of routine early invasive strategy seen at five years was attenuated during later follow-up, with no evidence of a difference in outcome at 10 years," the authors write.
The RITA-3 trial was funded by a competitive grant from the British Heart Foundation, which received a donation from Aventis Pharma. One author disclosed financial support from The Medicines Company.
Editorial (subscription or payment may be required)
Copyright © 2015 HealthDay. All rights reserved.